Clinical Research on the efficacy evaluation and the biomarker of nivolumab to an advance malignant melanoma

Trial Profile

Clinical Research on the efficacy evaluation and the biomarker of nivolumab to an advance malignant melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms CREATIVE; CSPOR
  • Most Recent Events

    • 11 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 28 Aug 2015 Planned initiation date changed from 1 Jan 2015 to 1 Sep 2015 as per University Hospital Medical Information Network - Japan.
    • 27 Aug 2015 Status changed from not yet recruiting to recruiting as per University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top